Blue Clay Capital Management’s Trinity Biotech TRIB Stock Holding History

Blue Clay Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$271K	Hold	137	–	–	0.31%	67
2016 Q2	$232K	Hold	137	–	–	0.27%	77
2016 Q1	$239K	Hold	137	–	–	0.23%	103
2015 Q4	$241K	Sell	137 -91	-40%	-$161K	0.2%	97
2015 Q3	$390K	Hold	228	–	–	0.31%	69
2015 Q2	$616K	Buy	228 +20	+10%	+$51.9K	0.35%	56
2015 Q1	$602K	Hold	208	–	–	0.31%	57
2014 Q4	$547K	Buy	+208	New	+$538K	0.4%	55

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Blue Clay Capital Management's TRIB Position: Q3 2016 in Review

Blue Clay Capital Management held its Trinity Biotech (TRIB) position steady in Q3 2016 at 137 shares worth $271K. The position accounts for 0.31% of the portfolio, ranked #67.

Blue Clay Capital Management first reported a position in TRIB in Q4 2014 and has held it in 8 quarters since. The position peaked at $616K in Q2 2015. 79 funds tracked by Wall St. Rank hold TRIB as of Q3 2016.

Blue Clay Capital Management held 137 shares of Trinity Biotech worth $271K as of Q3 2016.
Blue Clay Capital Management left its Trinity Biotech share count unchanged in Q3 2016.
Trinity Biotech made up 0.31% of Blue Clay Capital Management's portfolio in Q3 2016, its #67 holding.
Blue Clay Capital Management first reported a position in Trinity Biotech in Q4 2014 and has held it in 8 quarters since.
Blue Clay Capital Management's Trinity Biotech position peaked at $616K in Q2 2015.
79 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2016.

Based on Blue Clay Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.